Medication compliance and persistence: Terminology and definitions

被引:1590
作者
Cramer, Joyce A. [1 ]
Roy, Anuja [2 ]
Burrell, Anita [3 ]
Fairchild, Carol J. [4 ]
Fuldeore, Mahesh J. [5 ]
Ollendorf, Daniel A. [6 ]
Wong, Peter K.
机构
[1] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA
[2] W Virginia Univ, Morgantown, WV 26506 USA
[3] Sanofi Aventis, Paris, France
[4] Alcon Labs Inc, Ft Worth, TX 76101 USA
[5] TAP Pharmaceut, Lake Forest, IL USA
[6] PharMetrics, Watertown, MA USA
关键词
adherence; compliance; definitions; persistence; terminology;
D O I
10.1111/j.1524-4733.2007.00213.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: The aim of the study is to provide guidance regarding the meaning and use of the terms "compliance" and "persistence" as they relate to the study of medication use. Methods: A literature review and debate on appropriate terminology and definitions were carried out. Results: Medication compliance and medication persistence are two different constructs. Medication compliance (synonym: adherence) refers to the degree or extent of conformity to the recommendations about day-to-day treatment by the provider with respect to the timing, dosage, and frequency. It may be defined as "the extent to which a patient acts in accordance with the prescribed interval, and dose of a dosing regimen." Medication persistence refers to the act of continuing the treatment for the prescribed duration. It may be defined as "the duration of time from initiation to discontinuation of therapy." No overarching term combines these two distinct constructs. Conclusions: Providing specific definitions for compliance and persistence is important for sound quantitative expressions of patients' drug dosing histories and their explanatory power for clinical and economic events. Adoption of these definitions by health outcomes researchers will provide a consistent framework and lexicon for research.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 30 条
  • [1] [Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
  • [2] Persistence of use of lipid-lowering medications - A cross-national study
    Avorn, J
    Monette, J
    Lacour, A
    Bohn, RL
    Monane, M
    Mogun, H
    LeLorier, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18): : 1458 - 1462
  • [3] Defining compliance/adherence and persistence: ISPOR special interest working group
    Burrell, A
    Wong, P
    Ollendorf, D
    Fuldeore, M
    Roy, A
    Fairchild, C
    Cramer, JA
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A194 - A195
  • [4] The impact of compliance with osteoporosis therapy on fracture rates in actual practice
    Caro, JJ
    Ishak, KJ
    Huybrechts, KF
    Raggio, G
    Naujoks, C
    [J]. OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) : 1003 - 1008
  • [5] Tracking trends in secondary stroke prevention strategies
    Carswell, JL
    Beard, KA
    Chevrette, MM
    Pardue, CN
    Hess, DC
    Fagan, SC
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (02) : 215 - 219
  • [6] Catalan V S, 2000, Value Health, V3, P417, DOI 10.1046/j.1524-4733.2000.36006.x
  • [7] A systematic review of the associations between dose regimens and medication compliance
    Claxton, AJ
    Cramer, J
    Pierce, C
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (08) : 1296 - 1310
  • [8] Cramer J.A., 1995, AM J MANAG CARE, V1, P45
  • [9] Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
    Cramer, JA
    Amonkar, MM
    Hebborn, A
    Altman, R
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) : 1453 - 1460
  • [10] Results of a naturalistic study of treatment options: Switching atypical antipsychotic drugs or augmenting with valproate
    Cramer, JA
    Sernyak, M
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (06) : 905 - 914